Monograph Details
|
|
Immune System
> Immunization
|
|
VARIVAX |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
VAR. |
| Generic Name |
|
Varicella virus vaccine live, attenuated (Oka/Merck) (human and guinea pig cell cultures) with 1350 plaque-forming units (PFU) minimum per 0.5mL after reconstitution; for SC inj; lyophilized; preservative-free. |
| Indications |
|
Varicella (chickenpox) vaccination. |
| Children |
|
Give SC in deltoid area. Under 12 months: not recommended. 12 months–12 years: 1 dose of 0.5mL. |
| Adults |
|
Give SC in deltoid area. 1 dose of 0.5mL at elected date and a 2nd dose of 0.5mL 4–8 weeks later. |
| Contraindications |
|
See literature. Hypersensitivity to gelatin or neomycin. Active febrile infection. Active untreated tuberculosis. Primary or acquired immune deficiency. Immunosuppressant therapy. Blood dyscrasias. Bone marrow or lymphatic malignancy. Pregnancy (Cat.C) during and for 3 months after vaccination. |
| Precautions |
|
Have epinephrine inj available. Defer vaccination for at least 5 months after blood or plasma transfusions, immune globulins, or varicella zoster immune globulin (VZIG); avoid VZIG and other immune globulins for 2 months after immunization whenever feasible. HIV infection: see literature. Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications and Precautions. Avoid salicylates for 6 weeks after vaccination, immune globulins, transfusions. |
| Adverse Reactions |
|
Fever, local reactions, rash; others. |
| How Supplied |
|
Single-dose vials—1, 10 (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
